Henrik Schmidt

Part-time Lecturer, Clinical Associate Professor

Profile photoHenrik Schmidt
Part-time Lecturer, Clinical Associate Professor, Consultant


Department of Clinical Medicine - The Department of Oncology

Postal address:
Palle Juul-Jensens Boulevard 99
8200 Aarhus N
Denmark

Email: henrschm@rm.dk
Phone: +4578461682

Year of birth

1964

Educations

2007D.M.Sc degree in Medicine. The Faculty of Health Sciences, University of Aarhus, Denmark
2006Specialist in Medical Oncology and Radiotherapy, National Board of Health, Copenhagen, DK
2002Permission to practice independently as a physician: National Board of Health, Copenhagen, Denmark
1992Authorization as Physician. The Faculty of Health Sciences, School of Medicine, University of Aarhus, Denmark

Academic degrees

2007D.M.Sc. in Medicine

Research areas

Innumetherapy
Inflammatory cells and melanoma
Biomarkers in melanoma

Present position

2011-Associate Professor, Department of Oncology, Aarhus University, Denmark
2008-Consultant, Head of Clinical Research Unit, Department of Oncology, Aarhus University Hospital

Previous positions

2008Consultant, Head of Clinical Research Unit, Department of Oncology, Aarhus University Hospital, Denmark
2006-2008Staff specialist, Department of Oncology, Aarhus University Hospital, Denmark
2005-2006Senior Registrar, Department of Oncology, Aalborg
2002-2005Registrar, Department of Oncology, Aarhus University Hospital, Denmark
1997-2002Research fellow, Department of Oncology, Aarhus University Hospital, Denmark
1995-1996Registrar, Department of Oncology, Aarhus University Hospital, Denmark
1997Research fellow, Institute of Medical Microbiology and Immunology, Aarhus University Hospital, Danmark

Publications and repræsentations

Publications: 36, Peer-reviewed articles: 36, H-index: 16, Citations: 614, Scientific meeting presentations (oral) 25

Board memberships

Member of the board, Danish Melanoma Group

Organization of clinical trials

PRINCIPAL INVESTIGATOR:
A phase 1, Open label, dose escalation, safety and tolerability study of subcutaneous administration of recombinant human interleukin-21 in patients with stage IV melanoma or stage IV renal cell carcinoma (GCP).
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk stage III melanoma: A randomized, double-blind phase 3 trial of the EORTC melanoma group (GCP).
An Open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma (GCP).
A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma (GCP).
A Randomized, Open-Label Phase 3 Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.
A phase III (COMBI-AD) randomized double blind study of dabrafenib in COMBInation with trametinib versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-
positive melanoma after surgical resection.(GCP).

NATIONAL INVESTIGATOR:
An exploratory study to determine potential predictive markers of response and/or toxicity in patients with unresectable stage III or IV malignant melanoma randomized and treated with Ipilimumab (MDX-010) at two dose levels (GCP).
A Multicenter, Open-Label, Phase II study of Ipilimumab (MDX-010) extended treatment monotherapy or follow-up for patients previously enrolled in Ipilimumab (MDX-010) protocols (GCP).
A Randomized, multi dose, open-label, phase II study of BMS-663513 as a second-line monotherapy in subjects with previously treated unresectable stage III or stage IV melanoma (GCP).
A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Subjects with Previously Treated or Untreated Unresectable or Metastatic Melanoma (GCP).
A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects with Previously Untreated Unresectable or Metastatic Melanoma (GCP).
A phase III, randomized, double-blind study of nivolumab monotherapy or nivolumab combined with ipilimumab versus ipilimumab monotherapy in subjects with previously untreated unresectable or metastatic melanoma.

CO-INVESTIGATOR:
Phase III multinational trial, adjuvant Interferon trial, Nordic Melanoma Group.
A phase II trial of Interleukin 2, Interferon and Histamine, Danish Melanoma Group.
A phase I trial in metastatic melanoma: Adoptive transfer of allogeneic, cytotoxic T-lymphocytes equipped with a MART-1 T-cell receptor restricted by HLA-A2 (GCP), Danish Melanoma Group.
A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma (GCP), Danish Melanoma Group.

Supervision

Supervisor for 7 PhD. students at Faculty of Health Science, Aarhus University, Denmark
Supervisor for 2 PhD. students at Faculty of Health Science, Odense University, Denmark
Supervisor for 1 Cand.scient. San.-student at Faculty of Health Science, Aarhus University, Denmark
Supervisor for 2 Research year medical students at Faculty of Health Science, Aarhus University, Denmark

Evaluations

PhD. Thesis:
3 students at Faculty of Health Science, Copenhagen University, Copenhagen, Denmark

Chairman of PhD. Assessment committee:
2 students at Faculty of Health Science, Aarhus University, Denmark

Research year thesis:
2 students at Faculty of Health Science, Aarhus University, Denmark

Awards and grants

William Nielsen Foundation, Honorary Award (2013)
Hede Nielsen Foundation award together with Lars Bastholt and Inge Marie Svane (2010)
Bernhard Rasmussen and wife Meta Rasmussens mindelegat (2008)
ASCO Merit award at the ASCO meeting, Florida, USA (2005)

Major research grants

Danish Cancer Society:
Characterisation of subtypes of innate immune cells in ulcerated melanomas (2012-2015)


Organizer of meetings

Member of the organizing and scientific committee of the Nordic Melanoma Group meeting (2013)
Member of the organizing committee of the Clinical Research Unit meeting, Aarhus (2013)
Member of the organizing and scientific committee of the euMEET, Aarhus (2012)
Member of the organizing committee of the Clinical Research Unit meeting, Aarhus (2011)
Member of the organizing committee of the Clinical Research Unit meeting, Aarhus (2010)
Member of the organizing committee of the Clinical Research Unit meeting, Aarhus (2009)
Member of the organizing and scientific committee of the Nordic Melanoma Group meeting (2008)

Scientific journal involvements

Manuscript reviewer for:
Clinical Cancer Research
Journal of Investigative Dermatology
Clinical Chemistry
European Journal of Cancer
British Journal of Dermatology
Journal of Translational Medicine
Melanoma Research

Memberships

Danish Melanoma Group, board member (2012-)
American Society of Clinical Oncology (2008-)
European Organization for Research and Treatment of Cancer (EORTC) (2007-)
Nordic Melanoma Group (2007-)
Danish Society of Clinical Oncology
Danish Association for Cancer Research

Publications

KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Ferrucci, P. F., Di Giacomo, A. M., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Stephens, R., Svane, I. M., Lotem, M., Abu-Amna, M., Gasal, E., Ghori, R., Diede, S. J., Croydon, E. S., Ribas, A. & Ascierto, P. A., Dec 2020, In: Journal for immunotherapy of cancer. 8, 2, e001806.

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Rutkowski, P., Hassel, J. C., McNeil, C. M., Kalinka, E. A., Lebbé, C., Charles, J., Hernberg, M. M., Savage, K. J., Chiarion-Sileni, V., Mihalcioiu, C., Mauch, C., Arance, A., Cognetti, F., Ny, L., Schmidt, H., Schadendorf, D., Gogas, H., Zoco, J., Re, S., Ascierto, P. A. & Atkinson, V., Nov 2020, In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38, 33, p. 3937-3946 10 p.

Granzyme B degraded type IV collagen products in serum identify melanoma patients responding to immune checkpoint blockade

Jensen, C., Sinkeviciute, D., Madsen, D. H., Önnerfjord, P., Hansen, M., Schmidt, H., Karsdal, M. A., Svane, I. M. & Willumsen, N., Oct 2020, In: Cancers. 12, 10, 15 p., 2786.

Improved progression-free long-term survival of a nation-wide patient population with metastatic melanoma

Soerensen, A. V., Ellebaek, E., Bastholt, L., Schmidt, H., Donia, M. & Svane, I. M., Sep 2020, In: Cancers. 12, 9, 11 p., 2591.

Severe steroid refractory gastritis induced by Nivolumab: A case report

Vindum, H. H., Agnholt, J. S., Nielsen, A. W. M., Nielsen, M. B. & Schmidt, H., Apr 2020, In: World Journal of Gastroenterology. 26, 16, p. 1971-1978 8 p.

Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines

Christensen, J. N., Schmidt, H., Steiniche, T. & Madsen, M., 2020, In: Melanoma Research. 30, 1, p. 26-38 13 p.

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., van Schoiack, A., Lövgren, K., Warren, S., Jirström, K., Olsson, H., Pietras, K., Ingvar, C., Isaksson, K., Schadendorf, D., Schmidt, H., Bastholt, L., Carneiro, A., Wargo, J. A., Svane, I. M. & Jönsson, G., 2020, In: Nature. 577, 7791, p. 561-565 5 p.

The impact of patient involvement in research: a case study of the planning, conduct and dissemination of a clinical, controlled trial

Skovlund, P. C., Nielsen, B. K., Thaysen, H. V., Schmidt, H., Finset, A., Ahm Hansen, K. & Lomborg, K., 2020, In: Research Involvement and Engagement. 6, 16 p., 43.

A case report: metastasis of melanoma to the heart in an era of immunotherapy

Poulsen, C. B., Weile, K. S., Schmidt, H. & Poulsen, S. H., Dec 2019, In: European Heart Journal: Case Reports. 3, 4, p. 1-7 7 p.

Measured and genetically predicted plasma YKL-40 levels and melanoma mortality

Ismail, H., Helby, J., Hölmich, L. R., Chakera, A. H., Bastholt, L., Klyver, H., Sjøgren, P., Schmidt, H., Schöllhammer, L., Johansen, J. S., Nordestgaard, B. G. & Bojesen, S. E., Nov 2019, In: European Journal of Cancer. 121, p. 74-84 11 p.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S. & Testori, A., Sep 2019, In: European Journal of Cancer. 119, p. 1-10 10 p.

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

Bastholt, L., Schmidt, H., Bjerregaard, J. K., Herrstedt, J. & Svane, I. M., Sep 2019, In: European Journal of Cancer. 119, p. 122-131 10 p.

Immunterapi til patienter med malignt melanom og hjernemetastaser

Simonsen, L. T., Schmidt, A. M. S., Øllegaard, T. H., Svane, I. M., Bastholt, L., Luczak, A. A. & Schmidt, H., Jun 2019, In: Ugeskrift for Læger . 181, 24, V01190057.

Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status

Dabrosin, N., Sloth Juul, K., Bæhr Georgsen, J., Andrup, S., Schmidt, H., Steiniche, T., Heide Øllegaard, T. & Bønnelykke Behrndtz, L., Feb 2019, In: Melanoma Research. 29, 1, p. 30-37 8 p.

The real-world impact of modern treatments on the survival of patients with metastatic melanoma

Donia, M., Ellebaek, E., Øllegaard, T. H., Duval, L., Aaby, J. B., Hoejberg, L., Køhler, U. H., Schmidt, H., Bastholt, L. & Svane, I. M., Feb 2019, In: European Journal of Cancer. 108, p. 25-32 8 p.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Geukes Foppen, M. H., Hoejberg, L., Schmidt, H., Van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., Long, G. V., Atkinson, V., Blank, C. U. & Neyns, B., 2019, In: Annals of Oncology. 30, 7, p. 1154-1161 8 p.

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort

Bastholt, L., Svane, I. M., Bjerregaard, J. K., Herrstedt, J., Hróbjartsson, A. & Schmidt, H., 2019, In: European Journal of Cancer. 115, p. 61-67 7 p.

Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma

Bol, K. F., Ellebaek, E., Hoejberg, L., Bagger, M. M., Larsen, M. S., Klausen, T. W., Køhler, U. H., Schmidt, H., Bastholt, L., Kiilgaard, J. F., Donia, M. & Svane, I. M., 2019, In: Cancers. 11, 10, 11 p., 1489.

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Jensen, C., Madsen, D. H., Hansen, M., Schmidt, H., Svane, I. M., Karsdal, M. A. & Willumsen, N., 19 Dec 2018, In: Journal for immunotherapy of cancer. 6, 10 p.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

Long, G. V., Weber, J. S., Larkin, J., Atkinson, V., Grob, J-J., Schadendorf, D., Dummer, R., Robert, C., Márquez-Rodas, I., McNeil, C., Schmidt, H., Briscoe, K., Baurain, J-F., Hodi, F. S. & Wolchok, J. D., 1 Nov 2017, In: JAMA Oncology. 3, 11, p. 1511-1519 9 p.

Immunterapi er kræftbehandling med en helt ny bivirkningsprofil

Kondrup, M., Raunkilde, L., Svane, I. M., Schmidt, H. & Bastholt, L., 2 Oct 2017, In: Ugeskrift for Laeger. 179, 40, p. 2-6 5 p.

Quantification of microRNA-21 and microRNA-125b in melanoma tissue

Wandler, A., Riber-Hansen, R., Hager, H., Hamilton-Dutoit, S. J., Schmidt, H., Nielsen, B. S., Stougaard, M. & Steiniche, T., Oct 2017, In: Melanoma Research. 27, 5, p. 417-428 12 p.

Predictors of responses to immune checkpoint blockade in advanced melanoma

Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternes, N., Jegou, S., Woods, D. M., Sodre, A. L., Hansen, M., Meirow, Y., Sade-Feldman, M., Burra, A., Kwek, S. S., Flament, C., Messaoudene, M., Duong, C. P. M., Chen, L., Kwon, B. S., Anderson, A. C., Kuchroo, V. K., Weide, B., Aubin, F., Borg, C., Dalle, S., Beatrix, O., Ayyoub, M., Balme, B., Tomasic, G., Di Giacomo, A. M., Maio, M., Schadendorf, D., Melero, I., Dreno, B., Khammari, A., Dummer, R., Levesque, M., Koguchi, Y., Fong, L., Lotem, M., Baniyash, M., Schmidt, H., Svane, I. M., Kroemer, G., Marabelle, A., Michiels, S., Cavalcanti, A., Smyth, M. J., Weber, S., Eggermont, A. M. & Zitvogel, L., 19 Sep 2017, In: Nature Communications. 8, 13 p., 592.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Donia, M., Harbst, K., van Buuren, M., Kvistborg, P., Lindberg, M. F., Andersen, R., Idorn, M., Munir Ahmad, S., Ellebæk, E., Mueller, A., Fagone, P., Nicoletti, F., Libra, M., Lauss, M., Hadrup, S. R., Schmidt, H., Andersen, M. H., Thor Straten, P., Nilsson, J. A., Schumacher, T. N., Seliger, B., Jönsson, G. & Svane, I. M., 1 Sep 2017, In: Cancer Research. 77, 17, p. 4562-4566 5 p.

Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration

Bønnelykke-Behrndtz, M. L., Steiniche, T., Nørgaard, P., Danielsen, A. V., Damsgaard, T. E., Christensen, I. J., Bastholt, L., Møller, H. J. & Schmidt, H., Sep 2017, In: American Journal of Dermatopathology. 39, 9, p. 672-678 7 p.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M. & Levy, R., 15 Apr 2017, In: Clinical Cancer Research. 23, 8, p. 1929-1936 8 p.

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

Coens, C., Suciu, S., Chiarion-Sileni, V., Grob, J-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Bottomley, A., Kotapati, S., de Pril, V., Testori, A. & Eggermont, A. M. M., Mar 2017, In: Lancet Oncology. 18, 3, p. 393-403 11 p.

The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials

Donia, M., Kimper-Karl, M. L., Høyer, K. L., Bastholt, L., Schmidt, H. & Svane, I. M., Mar 2017, In: European journal of cancer (Oxford, England : 1990). 74, p. 89-95 7 p.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

D'Angelo, S. P., Larkin, J., Sosman, J. A., Lebbé, C., Brady, B., Neyns, B., Schmidt, H., Hassel, J. C., Hodi, F. S., Lorigan, P., Savage, K. J., Miller, W. H., Mohr, P., Marquez-Rodas, I., Charles, J., Kaatz, M., Sznol, M., Weber, J. S., Shoushtari, A. N., Ruisi, M., Jiang, J. & Wolchok, J. D., 10 Jan 2017, In: Journal of Clinical Oncology. 35, 2, p. 226-235 10 p.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Bastholt, L., Mortier, L., Thomas, L., Tahir, S., Hauschild, A., Hassel, J. C., Hodi, F. S., Taitt, C., de Pril, V., de Schaetzen, G., Suciu, S. & Testori, A., 10 Nov 2016, In: The New England Journal of Medicine. 375, 19, p. 1845-1855 11 p.

Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedre prognosen

Boyles, T. B., Svane, I. M., Bastholt, L. & Schmidt, H., 29 Aug 2016, In: Ugeskrift for Laeger. 178, 23, 4 p., V02160126 .

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Fløe, L. E., Svane, I. M., Bastholt, L. & Schmidt, H., 15 Aug 2016, In: Ugeskrift for Laeger. 178, 21, 4 p., V01160070 .

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma

Krogh, M., Christensen, I., Bouwhuis, M., Johansen, J. S., Nørgaard, P., Schmidt, H., Hansson, J., Suciu, S., Eggermont, A. M. M., Bastholt, L. & Nordic Melanoma Group and EORTC Melanoma Group, Aug 2016, In: Melanoma Research. 26, 4, p. 367-76 10 p.

Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma

Nielsen, P. S., Riber-Hansen, R., Schmidt, H. & Steiniche, T., 9 Apr 2016, In: Diagnostic Pathology. 11, p. 35

Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab

Bjoern, J., Juul Nitschke, N., Zeeberg Iversen, T., Schmidt, H., Fode, K. & Svane, I. M., Apr 2016, In: OncoImmunology. 5, 4, 10 p., e1100788.

Consumption of the Epidermis: A Suggested Precursor of Ulceration Associated With Increased Proliferation of Melanoma Cells

Bønnelykke-Behrndtz, M. L., Schmidt, H., Damsgaard, T. E., Christensen, I. J., Bastholt, L., Møller, H. J., Nørgaard, P. & Steiniche, T., Nov 2015, In: American Journal of Dermatopathology. 37, 11, p. 841-5 5 p.

The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer

Antonio, N., Bønnelykke-Behrndtz, M. L., Ward, L. C., Collin, J., Christensen, I. J., Steiniche, T., Schmidt, H., Feng, Y. & Martin, P., 2 Sep 2015, In: E M B O Journal. 34, 17, p. 2219-36 18 p.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Konto, C., Hoos, A., de Pril, V., Gurunath, R. K., de Schaetzen, G., Suciu, S. & Testori, A., May 2015, In: Lancet Oncology. 16, 5, p. 522-30 9 p.

MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin

Bønnelykke-Behrndtz, M. L., Steiniche, T., Damsgaard, T. E., Georgsen, J. B., Danielsen, A., Bastholt, L., Møller, H. J., Nørgaard, P. H. & Schmidt, H., Apr 2015, In: Melanoma Research. 25, 2, p. 113-8 6 p.

Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma

Køstner, A. H., Ellegaard, M-B. B., Christensen, I. J., Bastholt, L. & Schmidt, H., Mar 2015, In: Cancer Immunology, Immunotherapy. 64, 3, p. 349-55 7 p.

Ipilimumab til behandling af metastaserende melanoma

Ghasemi, H., Schmidt, H. & Stolle, L. B., 26 Jan 2015, In: Ugeskrift for Laeger. 177, 2A, p. 108-9 2 p.

Nivolumab in previously untreated melanoma without BRAF mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I. M., Atkinson, V. & Ascierto, P. A., 22 Jan 2015, In: The New England Journal of Medicine. 372, 4, p. 320-30 11 p.

Prognostic stratification of ulcerated melanoma: not only the extent matters

Bønnelykke-Behrndtz, M. L., Schmidt, H., Christensen, I. J., Damsgaard, T. E., Møller, H. J., Bastholt, L., Nørgaard, P. H. & Steiniche, T., Dec 2014, In: American Journal of Clinical Pathology. 142, 6, p. 845-56 12 p.

Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker

Lade-Keller, J., Riber-Hansen, R., Guldberg, P., Schmidt, H., Hamilton-Dutoit, S. J. & Steiniche, T., Jun 2014, In: Journal of Clinical Pathology. 67, 6, p. 520-8 9 p.

Ipilimumab til behandling af metastaserende melanom

Ghasemi, H., Schmidt, H. & Stolle, L. B., 5 Aug 2013, In: Ugeskrift for Laeger.

Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma

Nielsen, P. S., Riber-Hansen, R., Jensen, T. Ø., Schmidt, H. & Steiniche, T., 1 Mar 2013, In: Modern Pathology. 26, 3, p. 404-413 10 p.

Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma

Zukauskaite, R., Schmidt, H., Asmussen, J. T., Hansen, O. & Bastholt, L., 2013, In: Melanoma Research. 23, 1, p. 21-6 6 p.

Regression in cancer following fever and acute infection

Køstner, A. H., Johansen, R. F., Schmidt, H. & Mølle, I., 2013, In: Acta Oncologica. 52, 2, p. 455-7 3 p.

Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma

Jensen, T. Ø., Schmidt, H., Møller, H. J., Donskov, F., Høyer, M., Sjoegren, P., Christensen, I. J. & Steiniche, T., 1 May 2012, In: Cancer. 118, 9, p. 2476-2485

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

Shahabi, V., Whitney, G., Hamid, O., Schmidt, H., Chasalow, S. D., Alaparthy, S. & Jackson, J. R., 2012, In: Cancer Immunology, Immunotherapy. 61, 5, p. 733-7 5 p.

CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis

Weischer, M., Heerfordt, I. M., Bojesen, S. E., Eigentler, T., Garbe, C., Röcken, M., Hölmich, L. R., Schmidt, H., Klyver, H., Bastholt, L. & Nordestgaard, B. G., 2012, In: Journal of Investigative Dermatology. 132, 2, p. 299-303 5 p.

Completeness of TNM cancer staging for melanoma in the Danish Cancer Registry, 2004-2009

Frøslev, T., Grann, A. F., Olsen, M., Olesen, A. B., Schmidt, H., Friis, S. & Søgaard, M., 2012, In: Clinical Epidemiology. 4, S2, p. 5-10 6 p.

Interleukin-6 and melanoma

Hoejberg, L., Bastholt, L. & Schmidt, H., 2012, In: Melanoma Research. 22, 5, p. 327-33 7 p.

Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

Hoejberg, L., Bastholt, L., Johansen, J. S., Christensen, I. J., Gehl, J. & Schmidt, H., 2012, In: Melanoma Research. 22, 4, p. 287-93 7 p.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., Chasalow, S. D. & Berman, D., 2011, In: Journal of Translational Medicine. 9, p. 204

An immune-active tumor microenvironment favors clinical response to ipilimumab

Ji, R-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., Jackson, J. R. & Shahabi, V., 2011, In: Cancer Immunology, Immunotherapy.

Tumor and inflammation markers in melanoma using tissue microarrays: a validation study

Riber-Hansen, R., Schmidt, H., Hamilton-Dutoit, S. J., Steiniche, T. & Jensen, T. Ø., 2011, In: Melanoma Research Today. 21, 6, p. 509-15 7 p.

Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial

Schmidt, H., Brown, J., Mouritzen, U., Selby, P., Fode, K., Svane, I. M., Cook, G. P., Mollerup, D. H. & Geertsen, P. F., 1 Nov 2010, In: Clinical Cancer Research. 16, 21, p. 5312-9 8 p.

Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma

Jensen, T. O., Schmidt, H., Møller, H. J., Høyer, M., Maniecki, M. B., Sjøgren, P., Christensen, I. J. & Steiniche, T., 10 Jul 2009, In: Journal of Clinical Oncology. 27, 20, p. 3330-3337 8 p.

Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709)

Køllgaard, T., Duval, L., Schmidt, H., Kaltoft, K., Seremet, T., Andersen, M. H., von der Maase, H., Straten, P. T. & Hadrup, S. R., 2009, In: Cytotherapy. 11, 5, p. 631-41 10 p.

Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma

Jensen, T. Ø., Schmidt, H., Møller, H. J., Høyer, M., Maniecki, M. B., Sjoegren, P., Christensen, I. J. & Steiniche, T., 2009, In: Journal of Clinical Oncology. 27, 20, p. 3330-3337 7 p.

Participation in an unstructured supportive group as experienced by patients with advanced cancer disease: A preliminary study

Pedersen, A. F., Schmidt, H., Trautner, T. & Jensen, A. B., 2009, In: Acta Oncologica. 48, 7, p. 1074-7 4 p.

Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.

Schmidt, H., Suciu, S., Punt, C. J. A., Gore, M., Kruit, W., Patel, P., Lienard, D., von der Maase, H., Eggermont, A. M. M. & Keilholz, U., 2007, In: Journal of Clinical Oncology. 25, 12, p. 1562-9 7 p.

The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma.

Hernberg, M., Mattila, P. S., Rissanen, M., Hansson, J., Aamdal, S., Bastholt, L., von der Maase, H., Schmidt, H., Stierner, U. & Tarkkanen, J., 2007, In: Journal of Immunotherapy. 30, 7, p. 773-9 6 p.

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma

Duval, L., Schmidt, H., Kaltoft, K., Fode, K., Jensen, J. J., Sørensen, S. M., Nishimura, M. I. & Maase, H. V. D., 2006, In: Clinical Cancer Research. 12, 4, p. 1229-1236

Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma

Schmidt, H., Sørensen, B. S., Sjøgren, P., Christensen, I. J., Fode, K., Larsen, J., Nexø, E. & Maase, H. V. D., 2006, In: J. Invest. Dermatol.. 126, p. 849-854 6 p.

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma

Schmidt, H., Johansen, J. S., Gehl, J., Geertsen, P. F., Fode, K. & Maase, H. V. D., 2006, In: Syopa. 106, p. 1130-1139 10 p.

Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma

Schmidt, H., Johansen, J. S., Sjoegren, P., Christensen, I. B., Sørensen, B. S., Fode, K., Larsen, J. & Maase, H. V. D., 2006, In: J. Clin. Oncol.. 24, p. 798-804 7 p.

Tumour-associated macrophages are related to progression in patients with      metastatic melanoma following interleukin-2 based immunotherapy

Hansen, B. D., Schmidt, H., Maase, H. V. D., Sjøgren, P. & Hokland, M., 2006, In: Acta. Oncol.. 45, p. 400-405 6 p.

Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy

Schmidt, H., Sorensen, B. S., Fode, K., Nexo, E. & von der Maase, H., 1 Oct 2005, In: Melanoma Research. 15, 5, p. 409-16 8 p.

A phase II trial of low-dose total body irradiation and subcutaneous Interleukin-2 in metastatic melanoma

Safwat, A., Schmidt, H., Bastholt, L., Fode, K., Larsen, S., Aggerholm, N. & Maase, H. V. D., 2005, In: Radiother. Oncol.. 77, 2, p. 143-147

Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model

Schmidt, H., Bastholt, L., Geertsen, P., Christensen, I. J., Gehl, J. & Maase, H. V. D., 2005, In:   Br. J. Cancer. 93, p. 273-278 6 p.

The influence of immunohistochemistry on mRNA recovery from micro dissedted frozen and formalin-fixed, paraffin-embedded sections

Gjerdrum, L. M., Abrahamsen, H. N., Villegas, B., Sørensen, B. S., Schmidt, H. & Hamilton-Dutoit, S. J., Dec 2004, In: Diagnostic Molecular Pathology. 13, 4, p. 224-233 10 p.

S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma

Schmidt, H., Sørensen, B. S., Nexø, E. & Maase, H. V. D., Jun 2004, In: Melanoma Research. 14, 3, p. 211-15 5 p.

S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma

Schmidt, H., Sørensen, B. S., Nexø, E. & von der Maase, H., 2004, In: Melanoma Research. 14, 3, p. 211-5 4 p.

A phase II study of outpatients subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alfa in patients with metastatic melanoma

Schmidt, H., Larsen, S., Bastholt, L., Fode, K., Rytter, C. & Maase, H. V. D., Dec 2002, In: Annals of Oncology. 13, 12, p. 1919-1924 6 p.

Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma

Schmidt, H., Sørensen, H., Maase, H. V. D., Bang, C., Agger, R., Hokland, M. & Nexø, E., Dec 2002, In: Melanoma Research. 12, 6, p. 585-592 8 p.

Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study

Schmidt, H., Geertsen, P. F., Fode, K., Rytter, C., Bastholt, L. & von der Maase, H., 1 Feb 2000, In: Melanoma Research. 10, 1, p. 66-77 12 p.

Quantification of melanoma cell-specific MART-1 mRNA in peripheral blood by a calibrated competitive reverse transcription-PCR

Sørensen, B. S., Schmidt, H., von der Maase, H., Straten, P. T. & Nexø, E., 2000, In: Clinical Chemistry. 46, 12, p. 1923-8 5 p.